Arrowhead Pharmaceuticals (ARWR) Set to Announce Earnings on Thursday

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is expected to issue its Q4 2026 results after the market closes on Thursday, November 12th. Analysts expect the company to post earnings of ($1.52) per share and revenue of $61.18 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2026 earnings report for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:30 PM ET.

Arrowhead Pharmaceuticals Stock Down 0.5%

NASDAQ:ARWR opened at $49.00 on Wednesday. The firm has a market capitalization of $6.90 billion, a price-to-earnings ratio of -21.78 and a beta of 1.34. Arrowhead Pharmaceuticals has a 1-year low of $37.06 and a 1-year high of $95.49. The company has a current ratio of 5.90, a quick ratio of 5.90 and a debt-to-equity ratio of 1.77. The business’s fifty day moving average price is $65.53 and its 200 day moving average price is $71.28.

Insider Activity at Arrowhead Pharmaceuticals

In other news, Director Adeoye Olukotun sold 2,000 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total transaction of $173,920.00. Following the transaction, the director owned 31,600 shares in the company, valued at $2,747,936. This represents a 5.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Michael Perry sold 11,600 shares of the firm’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $87.30, for a total transaction of $1,012,680.00. Following the transaction, the director owned 111,459 shares in the company, valued at $9,730,370.70. This represents a 9.43% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 3.60% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Chardan Capital reaffirmed a “buy” rating and set a $115.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Thursday, October 15th. Morgan Stanley increased their price target on shares of Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. The Goldman Sachs Group initiated coverage on shares of Arrowhead Pharmaceuticals in a research report on Thursday, September 24th. They issued a “neutral” rating and a $74.00 price target for the company. HC Wainwright restated a “buy” rating and set a $120.00 price target on shares of Arrowhead Pharmaceuticals in a report on Thursday, October 15th. Finally, B. Riley Financial boosted their price objective on shares of Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Arrowhead Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $99.07.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals is a biotechnology company that develops medicines using RNA interference (RNAi), a biological process that can reduce the production of specific proteins by silencing the genes that encode them. Its proprietary Targeted RNAi Molecule (TRiM) platform is designed to deliver RNAi treatments to targeted tissues. The company’s research and development programs address a range of conditions, including liver, cardiometabolic, pulmonary and neurological diseases. Its work centers on investigational medicines and drug-development partnerships.